2. Antibody-drug Conjugate/ADC Related Immunology/Inflammation
  3. ADC Antibody CD19
  4. Inebilizumab

Inebilizumab is an anti-CD19 monoclonal antibody (mAb) with enhanced antibody-dependent cell-mediated cytotoxicity against B cells. Inebilizumab can be used for multiple sclerosis and neuromyelitis optica research.

For research use only. We do not sell to patients.

CAS No. : 1299440-37-1

Size Price Stock Quantity
1 mg USD 240 In-stock
5 mg USD 620 In-stock
10 mg USD 995 In-stock
50 mg   Get quote  
100 mg   Get quote  

* Please select Quantity before adding items.

This product is a controlled substance and not for sale in your territory.

Customer Review

Based on 1 publication(s) in Google Scholar

Other Forms of Inebilizumab:

Inebilizumab Related Antibodies

Top Publications Citing Use of Products

1 Publications Citing Use of MCE Inebilizumab

  • Biological Activity

  • Purity & Documentation

  • References

  • Customer Review

Description

Inebilizumab is an anti-CD19 monoclonal antibody (mAb) with enhanced antibody-dependent cell-mediated cytotoxicity against B cells. Inebilizumab can be used for multiple sclerosis and neuromyelitis optica research[1].

Isotype

Human IgG1 kappa
Recommend Isotype Controls
Species

Humanized
In Vitro

Inebilizumab is derived from the mouse anti-human mAb HB12b, which had already shown impressive activity in depletion of B cells in transgenic mice carrying the human CD19 gene (hCD19 Tg)[1].
Inebilizumab potently depletes CD19-expressing B cells, including primary human B cells, B cell lines derived from multiple tumor types, and neoplastic B cells[1].
Inebilizumab demonstrates equal or better activity than Rituximab (HY-P9913) in depletion of human primary B cells in autologous ADCC assays and shows potent ADCC activity against human in vitro-differentiated and primary plasma cells[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Inebilizumab Related Antibodies
In Vivo

Inebilizumab (MEDI-551) (0-10 mg/kg; i.v.; once) depletes B cells from blood and spleen by mouse macrophages in vivo and phagocytosis of murine B cells ex vivo[2].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model: huCD19/CD20 double Tg mice[2]
Dosage: 0.5, 2, or 10 mg/kg
Administration: Tail vein injection, once
Result: Depleted B cells from blood and spleen, B-cell depletion in blood and spleen was maintained for more than 2 weeks after a single 10 mg/kg administration (better than Rituximab). Resulted in a substantial reduction (on average by 91.4% by day 3) in BM B220+muCD19+ B cells. Led to depletion of B cell by mouse macrophages.
Clinical Trial
CAS No.
Appearance

Liquid

Color

Colorless to light yellow

SMILES

[Inebilizumab]
Shipping

Shipping with dry ice.
Storage

Please store the product under the recommended conditions in the Certificate of Analysis.
Format
  • Human IgG1 kappa
Biological Activity
  • Inebilizumab has a significant ADCC effect on CHOK1-hCD19 cells in a dose-dependent manner.The EC50 for this effect is 61.53 ng/mL.
  • Loaded Inebilizumab on AHC2 biosensor, can bind CD19 Protein, Human (HEK293, His, HY-P74330) with an affinity constant of 1.240E-09 M as determined in BLI assay.
Purity & Documentation

Purity: 99.00%

COA (232 KB)

Inhibitory Antibodies User Guide (602 KB)
References
  • No file chosen (Maximum size is: 1024 Kb)
  • If you have published this work, please enter the PubMed ID.
  • Your name will appear on the site.

Inebilizumab Related Classifications

  • Molarity Calculator

  • Dilution Calculator

The molarity calculator equation

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Mass   Concentration   Volume   Molecular Weight *
= × ×

The dilution calculator equation

Concentration (start) × Volume (start) = Concentration (final) × Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2

Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
× = ×
C1   V1   C2   V2
Help & FAQs
  • Do most proteins show cross-species activity?

    Species cross-reactivity must be investigated individually for each product. Many human cytokines will produce a nice response in mouse cell lines, and many mouse proteins will show activity on human cells. Other proteins may have a lower specific activity when used in the opposite species.

Keywords:

Inebilizumab1299440-37-1ADC AntibodyCD19multiple sclerosisneuromyelitis opticamyasthenia gravisautoantibody-mediated encephalitisRituximabInhibitorinhibitorinhibit

Your Recently Viewed Products:

Inquiry Online

Your information is safe with us. * Required Fields.

Product Name

  

Salutation

Applicant Name *

 

Email Address *

Phone Number *

 

Organization Name *

Department *

 

Requested quantity *

Country or Region *

      

Remarks

Bulk Inquiry

Inquiry Information

Product Name:
Inebilizumab
Cat. No.:
HY-P99113
Quantity:
MCE Japan Authorized Agent:

Customer Review

Thank You for Your Feedback!

Request for HNMR Report

Please fill out this form to request the QC report. We will send it to your Email address shortly.

Your information is safe with us. * Required Fields.

Product Name

  

Lot #

Applicant Name *

 

Email Address *

Phone Number

 

Department *

Organization Name *

 

Country or Region *

Remarks

Request for HNMR Report

We have received your request and will respond to you as soon as possible.